Detection test for Zika virus, 4/16
April 2016—Siemens Healthcare Diagnostics plans to release a genetic assay designed to test for the presence of the Zika virus.
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2016—Siemens Healthcare Diagnostics plans to release a genetic assay designed to test for the presence of the Zika virus.
April 2016—Hardy Diagnostics announced the acquisition of Wichita Falls, Tex.-based GG&B Company, maker of automated microscope slide stainers for laboratory use.
April 2016—Qiagen introduced more than 170 new QIAseq Targeted RNA Panels for gene expression profiling.
April 2016—Enzo Life Sciences now offers Digoxigenin-dUTP and Digoxigenin-UTP, digoxigenin-labeled nucleotides that are suitable for a variety of molecular biology applications.
March 2016—Ambry Genetics has launched a suite of five genetic tests for neurodevelopmental conditions: IDNext, a broad panel of 140 genes known to be associated with both syndromic and nonsyndromic intellectual disability; AutismFirst, a targeted panel of 16 genes recognized by the American College of Genetics and Genomics as associated with syndromic
March 2016—Mopec has developed a powered hydraulic cadaver carrier capable of transporting up to 700 pounds with a simple light touch. Powered by a battery-operated motorized base, the Mopec JA800 Powered Hydraulic Cadaver Carrier easily navigates corners, ramps, and doors as it safely moves without manual force, allowing even small operators to transport effortlessly, free from back and body strain.
March 2016—Bio-Rad Laboratories and Illumina announced an exclusive partnership to develop a comprehensive next-generation sequencing workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells.
March 2016—The Thermo Scientific Medifuge is a benchtop centrifuge that features a two-in-one hybrid rotor with interchangeable fixed-angle and swinging buckets to facilitate quick and convenient switching between applications. When coupled with the Thermo Scientific DualSpin rotor, the centrifuge provides the flexibility to perform several applications on a single platform.
March 2016—Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multi-template analysis LiquidBiopsy platform.
March 2016—Immucor, in collaboration with Sirona Genomics, announced the launch of Mia Fora NGS, a high-resolution human leukocyte antigen typing solution that provides accurate, comprehensive coverage of 11 HLA genes. With a workflow that can be automated or run manually, Mia Fora NGS is adapted for use on the Illumina MiSeq next-generation sequencing platform and is available for research use only in the U.S. and other countries, with CE mark anticipated shortly.